Alembic Pharma Q2 net surges 81% to ₹335 crore
“U.S. business was driven by strong volume growth and new launches. In U.S. Branded, we are encouraged by the traction building across our existing portfolio,” said
Account subscription benefits alongside Premium Stories, Editorials, Opinions and more.
Unlock these with Subscription
The View From India Looking at World Affairs from the Indian perspective.
First Day First Show News and reviews from the world of cinema and streaming.
Today's Cache Your download of the top 5 technology stories of the day.
Science For All The weekly newsletter from science writers takes the jargon out of science and puts the fun in!
Data Point Decoding the headlines with facts, figures, and numbers
THEdge At the cutting edge of education and careers
Health Matters Ramya Kannan writes to you on getting to good health, and staying there
Gender Agenda Stories from beyond the binary.
The Hindu On Books Books of the week, reviews, excerpts, new titles and features.
Published - November 05, 2026 04:50 pm IST - HYDERABAD
The expansion of the collaboration with DifGen provides near-term commercial opportunities and access to U.S. manufacturing capabilities. | Photo Credit: The Hindu
Alembic Pharmaceuticals shares were in the spotlight Wednesday after the generic drugmaker reported more than 81% year-on-year surge in consolidated net profit to ₹335 crore during September quarter.
The profit came on a 36% increase in the revenue from operations to ₹2,603 crore.
The company also announced expansion of its collaboration with DifGen Pharmaceuticals that will help it sharpen focus on the key U.S. market.
Alembic shares touched 20% intra-day before paring gains to close nearly 13% higher at ₹907.20 apiece on the BSE.
On the Q2 FY27 results, Managing Director Pranav Amin said the “U.S business was driven by strong volume growth and new launches.
In U.S.
Branded, we are encouraged by the traction building across our existing portfolio.”
The expansion of the collaboration with DifGen provides near-term commercial opportunities and access to U.S. manufacturing capabilities besides being a capital efficient way to deepen the pipeline, strengthen quality and sustainability of Alembic’s U.S. business growth, he said.
Building on the existing relationship, including a joint venture in Canada, the expanded collaboration will combine DifGen’s development and U.S. manufacturing capabilities with Alembic’s U.S. commercial platform.
DifGen will lead development, regulatory, manufacturing and supply activities, while Alembic will manufacture select products and commercialise the portfolio in the US.
“The portfolio expands Alembic’s exposure to differentiated opportunities, particularly in transdermal systems, complex injectables and other specialised dosage forms,” Mr.Amin said.
business (general) / pharmaceutical / generic drugs / medicine / earnings / company information
Terms & conditions | Institutional Subscriber
Comments have to be in English, and in full sentences.
They cannot be abusive or personal.
Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform.
If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles.
If you do not have an account please register and login to post comments.
Users can access their older comments by logging into their accounts on Vuukle.
Full detailed coverage is shown on the council website above. Source attribution: The Hindu – Business.
Back to all council news
